{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-000966","form_type":"8-K","ticker":"CLDX","cik":"0000744218","company_name":"Celldex Therapeutics, Inc.","filed_at":"2024-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.852169+00:00","generated_at":"2026-06-05T16:01:47.647572+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Celldex Q4 2023 net loss $43.3M; cash $423.6M; Phase 3 CSU study planned for summer 2024","bullets":["Q4 2023 net loss $43.3M ($0.83/share) vs $26.5M ($0.56) in Q4 2022; FY net loss $141.4M ($2.92/share).","Revenue $4.1M in Q4 2023 vs $1.6M in Q4 2022, primarily from Rockefeller University manufacturing agreements.","Cash, cash equivalents and marketable securities $423.6M at Dec 31, 2023 vs $235.3M at Sep 30, 2023; $216.2M raised in Nov 2023 offering.","Barzolvolimab: Positive Phase 2 CSU 12-week data; Phase 3 CSU studies expected to start summer 2024; 52-week data in 2H 2024.","Phase 2 CIndU enrollment nearing completion (data 2H 2024); Phase 2 PN study to start early 2024; cash runway into 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-000966","json":"https://secwatch.observer/filing/0001171843-24-000966.json","markdown":"https://secwatch.observer/filing/0001171843-24-000966.md","text":"https://secwatch.observer/filing/0001171843-24-000966.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744218/000117184324000966/0001171843-24-000966-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744218/000117184324000966/f8k_022524.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T16:01:47.647572+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"af059f24438e9b85f44c381822457b7e1c45f5ed","claim":"Celldex Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.","evidence_excerpt":"On February 26, 2024, Celldex Therapeutics, Inc. (the \"Company\") issued a press release announcing its financial results for the fourth quarter and year ended 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/744218/000117184324000966/0001171843-24-000966-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}